Drug Shortage Report for TEVA-NABILONE
Report ID | 149942 |
Drug Identification Number | 02392925 |
Brand name | TEVA-NABILONE |
Common or Proper name | NABILONE 0.25MG CAPS |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | NABILONE |
Strength(s) | 0.25MG |
Dosage form(s) | CAPSULE |
Route of administration | ORAL ORAL |
Packaging size | 50 |
ATC code | A04AD |
ATC description | ANTIEMETICS AND ANTINAUSEANTS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2021-11-24 |
Estimated end date | 2022-04-30 |
Actual end date | 2021-11-30 |
Shortage status | Resolved |
Updated date | 2021-12-02 |
Company comments | Original April '22 date for release was an error |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2021-11-25 | English | Compare |
v2 | 2021-11-25 | French | Compare |
v3 | 2021-12-02 | English | Compare |
v4 | 2021-12-02 | French | Compare |
Showing 1 to 4 of 4